Related Experiment Video

Updated: Jun 1, 2026

A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats
07:04

A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats

Published on: August 19, 2018

PKU: high plasma phenylalanine concentrations are associated with increased prevalence of mood swings

Karen Anjema1, Margreet van Rijn, Paul H Verkerk

  • 1Beatrix Children's Hospital, University Medical Centre Groningen, University of Groningen, Section of Metabolic Diseases, The Netherlands.

Molecular Genetics and Metabolism
|June 17, 2011
PubMed

Insights

High phenylalanine levels in phenylketonuria (PKU) are linked to mood swings. This study found a connection between phenylalanine concentrations and behavioral changes, particularly mood fluctuations, in PKU patients.

Area of Science:

  • Metabolic disorders
  • Neuroscience
  • Behavioral science

Background:

  • Phenylketonuria (PKU) is a metabolic disorder.
  • Limited understanding of the relationship between plasma phenylalanine and behavior in PKU.
  • Behavioral disturbances can impact quality of life for PKU patients.

Purpose of the Study:

  • To investigate the association between high plasma phenylalanine levels and behavioral disturbances in early-treated PKU patients.
  • To determine if patients or their close environment report behavioral changes related to phenylalanine concentrations.
  • To explore specific behaviors like hyperactivity, mood swings, and social interaction patterns.

Main Methods:

  • Study included 48 early-treated PKU patients (age range 0-35 years).
  • Plasma phenylalanine concentrations were measured.
  • Standardized questionnaires assessed behavioral changes (hyperactivity, mood swings, etc.) reported by patients and their close environment.
  • Interviewer and respondents were blinded to phenylalanine levels.

Main Results:

  • Patients reported less behavioral deviance than their close environment.
  • A positive association was found between phenylalanine concentrations and mood swings in the total group and in patients under 12 years old.
  • No statistically significant relationships were found between temporary high phenylalanine levels and hyperactivity, annoying behavior, or introvert/extravert behavior.

Conclusions:

  • Plasma phenylalanine concentrations are positively associated with mood swings in PKU patients.
  • Behavioral monitoring in PKU should consider mood fluctuations.
  • Further research may explore other behavioral aspects and their relation to phenylalanine levels.
Abstract

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures10:38

Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures

Published on: May 9, 2020

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Bipolar Disorder01:30

Bipolar Disorder

Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...